Medimibi: Uses, Dosage & Side Effects
A technetium Tc-99m sestamibi radiopharmaceutical kit used for myocardial perfusion imaging, parathyroid scintigraphy, and breast imaging in nuclear medicine
Medimibi is a radiopharmaceutical kit containing the active substance tetrakis(2-methoxy-2-methylpropyl isocyanide) copper(I) tetrafluoroborate, which when labeled with technetium-99m produces technetium Tc-99m sestamibi, a widely used diagnostic imaging agent in nuclear medicine. Medimibi is primarily used for myocardial perfusion imaging (MPI) to detect coronary artery disease and assess heart muscle viability, for parathyroid scintigraphy to locate overactive parathyroid glands in hyperparathyroidism, and as an adjunct breast imaging agent. After intravenous injection, the radiolabeled compound accumulates in metabolically active tissues proportional to blood flow, allowing gamma camera visualization of perfusion patterns and tissue function. Medimibi is administered exclusively in authorized nuclear medicine facilities by trained healthcare professionals.
Quick Facts: Medimibi
Key Takeaways
- Medimibi (technetium Tc-99m sestamibi) is a well-established radiopharmaceutical used primarily for myocardial perfusion imaging (MPI) to diagnose coronary artery disease, assess myocardial viability, and guide treatment decisions in patients with suspected or known heart disease.
- Beyond cardiac imaging, Medimibi is used for parathyroid scintigraphy to localize adenomas in primary hyperparathyroidism and for breast scintigraphy (scintimammography) as a supplementary tool when mammographic findings are inconclusive.
- The agent is prepared fresh in nuclear medicine departments by adding technetium-99m pertechnetate to the Medimibi kit, and is administered exclusively by trained personnel in licensed facilities – it is never self-administered by patients.
- Side effects are uncommon and generally mild; the most frequently reported include a transient metallic taste, headache, and flushing. The radiation dose from a standard study is comparable to a few years of natural background radiation.
- Medimibi should generally be avoided during pregnancy due to radiation exposure to the fetus, and breastfeeding mothers should interrupt nursing for at least 24 hours after administration to minimize the infant’s radiation dose.
What Is Medimibi and What Is It Used For?
Medimibi is a diagnostic radiopharmaceutical supplied as a kit for the preparation of technetium Tc-99m sestamibi injection. The kit contains the non-radioactive precursor tetrakis(2-methoxy-2-methylpropyl isocyanide) copper(I) tetrafluoroborate along with excipients necessary for the radiolabeling process. When sodium pertechnetate Tc-99m (obtained from a molybdenum-99/technetium-99m generator) is added to the Medimibi vial and heated, a ligand-exchange reaction occurs in which the copper is displaced and replaced by technetium-99m, yielding the final radiopharmaceutical product: technetium Tc-99m sestamibi, a lipophilic monovalent cationic complex.
Technetium Tc-99m sestamibi was first developed in the 1980s and received regulatory approval for clinical use in the early 1990s. Since then, it has become one of the most widely used radiopharmaceuticals in nuclear medicine worldwide, with millions of studies performed annually. The compound’s diagnostic utility derives from its unique pharmacokinetic properties: after intravenous injection, Tc-99m sestamibi is rapidly cleared from the blood and accumulates in tissues proportional to regional blood flow and cellular viability. The mechanism of cellular uptake involves passive diffusion across cell membranes driven by the negative electrical potential maintained across the plasma membrane and mitochondrial membranes. Inside cells, the tracer accumulates predominantly within mitochondria, where the strongly negative transmembrane potential traps the lipophilic cation. Tissues with high mitochondrial density and metabolic activity – such as viable heart muscle, overactive parathyroid tissue, and certain tumors – show increased and prolonged uptake of the agent.
The physical properties of technetium-99m make it an ideal radionuclide for single-photon emission computed tomography (SPECT) imaging. It emits 140 keV gamma rays, which are optimally suited for detection by modern gamma cameras, and has a physical half-life of approximately 6.02 hours – long enough to complete imaging protocols but short enough to limit patient radiation exposure. After imaging, the radioactivity decays naturally and is eliminated from the body primarily through hepatobiliary excretion into the intestines and, to a lesser extent, through the kidneys.
Myocardial Perfusion Imaging (MPI)
The primary clinical application of Medimibi is myocardial perfusion imaging (MPI), a non-invasive nuclear cardiology technique that assesses blood flow to the heart muscle at rest and during stress (exercise or pharmacological). MPI with Tc-99m sestamibi is considered a cornerstone investigation in the diagnosis and management of coronary artery disease (CAD) and is recommended by major international guidelines including those of the European Society of Cardiology (ESC), the American College of Cardiology (ACC), and the American Heart Association (AHA).
During a typical MPI study, the patient receives two separate injections of Medimibi: one at rest and one during stress (either exercise on a treadmill or bicycle, or pharmacological stress using agents such as adenosine, dipyridamole, or regadenoson for patients unable to exercise adequately). Gamma camera images acquired after each injection reveal the distribution of blood flow throughout the heart muscle. In a normal study, tracer uptake is homogeneous across all regions of the myocardium during both stress and rest. In the presence of significant coronary artery stenosis, areas of reduced blood flow (perfusion defects) appear as regions of decreased tracer uptake during stress compared with rest, indicating stress-induced myocardial ischemia. Fixed perfusion defects (present during both stress and rest) suggest previous myocardial infarction (heart attack) with scar tissue.
MPI with Tc-99m sestamibi has been extensively validated in large clinical trials. A meta-analysis published in the Journal of the American College of Cardiology reported a pooled sensitivity of 87% and specificity of 73% for the detection of angiographically significant coronary artery disease. The addition of gated SPECT (where images are synchronized with the cardiac cycle) provides simultaneous assessment of left ventricular function, including ejection fraction, wall motion, and wall thickening, significantly enhancing the diagnostic and prognostic value of the study. MPI results are powerful predictors of future cardiac events: patients with normal perfusion have an annual cardiac event rate of less than 1%, providing important reassurance, while those with extensive ischemia are at substantially higher risk and may benefit from revascularization procedures.
Parathyroid Scintigraphy
Medimibi is also established as the primary radiopharmaceutical agent for parathyroid scintigraphy, used to localize overactive (hyperfunctioning) parathyroid tissue in patients with primary hyperparathyroidism. Primary hyperparathyroidism, most commonly caused by a single parathyroid adenoma (approximately 85% of cases), results in excessive parathyroid hormone (PTH) secretion and elevated blood calcium levels. Accurate preoperative localization of the culprit gland is essential for planning minimally invasive parathyroidectomy, which has become the surgical standard of care.
The scintigraphic technique exploits the differential washout pattern of Tc-99m sestamibi between thyroid tissue and parathyroid adenomas. Both the thyroid gland and parathyroid adenomas initially take up the tracer after injection. However, the thyroid clears the tracer relatively quickly, while parathyroid adenomas – which have a particularly high mitochondrial density due to their metabolically active oxyphil cells – retain the tracer for a prolonged period. By acquiring early images (at approximately 15 minutes post-injection) and delayed images (at 2–3 hours), the characteristic pattern of persistent focal uptake corresponding to a parathyroid adenoma can be identified against the background of fading thyroid activity.
Contemporary parathyroid imaging protocols often combine Tc-99m sestamibi SPECT/CT (single-photon emission computed tomography combined with computed tomography) for improved anatomical localization, achieving sensitivity rates of 80–95% for single adenomas. This imaging modality has transformed parathyroid surgery by enabling focused surgical approaches with smaller incisions, shorter operative times, and reduced morbidity compared with traditional bilateral neck exploration.
Breast Imaging (Scintimammography)
Medimibi is approved as an adjunct imaging agent for the evaluation of breast lesions in patients with inconclusive mammographic findings. Scintimammography (also known as molecular breast imaging or breast-specific gamma imaging) exploits the increased mitochondrial activity and blood flow in malignant breast tissue, which leads to preferential accumulation of Tc-99m sestamibi. The technique is particularly valuable in women with dense breast tissue, where mammographic sensitivity is reduced, and may be used when biopsy results are equivocal or when further evaluation is needed before proceeding to more invasive procedures. Studies have reported sensitivity of 85–95% for tumors larger than 1 cm, though sensitivity is lower for smaller lesions.
Tc-99m sestamibi-based myocardial perfusion imaging remains one of the most extensively validated and widely used non-invasive cardiac diagnostic tests in clinical practice. Guidelines from the European Society of Cardiology and the American College of Cardiology recommend MPI as a first-line functional imaging test for the evaluation of suspected stable coronary artery disease in intermediate-risk patients. The combination of perfusion assessment and functional data from gated SPECT makes it a uniquely comprehensive diagnostic tool.
What Should You Know Before Receiving Medimibi?
Contraindications
The primary contraindication to Medimibi is known hypersensitivity (allergy) to the active substance (tetrakis(2-methoxy-2-methylpropyl isocyanide) copper(I) tetrafluoroborate or technetium Tc-99m sestamibi after labeling) or to any of the excipients in the formulation. Allergic reactions to Tc-99m sestamibi are extremely rare, with an estimated incidence of less than 1 in 100,000 administrations, but have been reported and can include urticaria (hives), rash, angioedema, and in very rare cases, anaphylaxis.
There are no absolute disease-specific contraindications to the diagnostic use of Medimibi itself. However, when MPI is performed with exercise or pharmacological stress, the stress component has its own contraindications that must be carefully evaluated. For example, pharmacological vasodilator stress with adenosine or dipyridamole is contraindicated in patients with severe bronchospastic lung disease (asthma or severe COPD), second- or third-degree atrioventricular block (without a pacemaker), systolic blood pressure below 90 mmHg, or recent acute myocardial infarction or unstable angina. Exercise stress testing is contraindicated in patients with acute myocardial infarction within the preceding 2–3 days, unstable angina not previously stabilized, symptomatic severe aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolism, and acute myocarditis or pericarditis.
Warnings and Precautions
Medimibi contains radioactive material. It should only be used when the expected diagnostic benefit outweighs the radiation risk. The principle of ALARA (As Low As Reasonably Achievable) must be applied. Adequate hydration before and after the procedure, along with frequent urination, helps reduce radiation exposure to the bladder and overall effective dose.
Before receiving Medimibi, discuss the following with your healthcare provider:
- Radiation exposure: Every diagnostic procedure involving ionizing radiation carries a small statistical risk of inducing cancer in the long term. The effective dose from a typical one-day rest-stress Tc-99m sestamibi MPI protocol is approximately 8–12 millisieverts (mSv), depending on the administered activities and the specific protocol used. To put this in context, the average annual background radiation dose is approximately 2.4 mSv. Modern imaging protocols, including stress-first approaches and CZT (cadmium zinc telluride) camera technology, can reduce radiation doses to as low as 3–5 mSv. Your nuclear medicine physician will ensure the lowest activity consistent with obtaining a diagnostic quality study.
- Kidney impairment: While Tc-99m sestamibi is primarily cleared through the hepatobiliary route, some urinary excretion does occur. Patients with significant renal impairment may have slightly altered biodistribution, but dose adjustment is generally not required. Adequate hydration is particularly important in these patients.
- Liver disease: Hepatobiliary excretion is the primary clearance pathway. In patients with significant liver disease, delayed hepatic clearance may result in increased background activity in the liver and intestines, potentially affecting image quality. The nuclear medicine physician may adjust the imaging protocol accordingly.
- Allergy history: Although extremely rare, allergic reactions have been reported. Inform your healthcare team if you have a history of allergic reactions to any radiopharmaceutical or medical product.
Pregnancy and Breastfeeding
Medimibi should not be administered to pregnant women unless the clinical benefit clearly outweighs the potential radiation risk to the developing fetus. Ionizing radiation can be harmful to the embryo or fetus, particularly during the first trimester when organogenesis is occurring. All women of childbearing potential should be asked about the possibility of pregnancy before the procedure, and a pregnancy test should be performed when pregnancy cannot be excluded. If the procedure is clinically essential, every effort should be made to minimize the administered activity and thus the radiation dose.
Technetium-99m labeled compounds are excreted in breast milk. Breastfeeding mothers should interrupt breastfeeding for at least 24 hours following the administration of Medimibi. Breast milk expressed during this 24-hour period should be discarded and not fed to the infant. Breastfeeding can be safely resumed after the 24-hour interruption period, by which time the radioactivity in the milk will have decayed to negligible levels. It is advisable to consider expressing and storing breast milk before the procedure so the infant can be fed during the interruption period.
Children and Adolescents
Medimibi can be used in pediatric patients when clinically indicated, though the use of nuclear medicine procedures in children requires careful justification given their greater sensitivity to ionizing radiation compared with adults. Pediatric dosing is calculated based on body weight according to the recommendations of the European Association of Nuclear Medicine (EANM) Dosage Card or the North American Consensus Guidelines. The ALARA principle is particularly important in pediatric imaging, and alternative non-ionizing imaging modalities should be considered when they can provide equivalent diagnostic information.
Driving and Operating Machinery
Medimibi itself does not affect the ability to drive or operate machinery. However, patients should be aware that the associated stress test (exercise or pharmacological) may cause temporary fatigue, dizziness, or other symptoms. If pharmacological stress agents such as adenosine or dipyridamole are used, patients should not drive or operate heavy machinery until they have fully recovered from the effects of the stress agent, typically within 30–60 minutes after the procedure. Aminophylline may be administered to reverse the effects of dipyridamole if needed.
How Does Medimibi Interact with Other Drugs?
The pharmacokinetic interactions of Tc-99m sestamibi with other drugs are minimal because the compound is not metabolized by hepatic enzymes and does not compete with common metabolic pathways. However, the clinical context in which Medimibi is used – particularly myocardial perfusion imaging with stress testing – means that several classes of medications can significantly affect the diagnostic quality of the study. These interactions are primarily pharmacodynamic rather than pharmacokinetic, affecting either the myocardial uptake pattern or the stress test itself.
It is essential to discuss all medications, supplements, and dietary habits with your nuclear medicine physician and referring doctor before the procedure. The decision to withhold medications depends on the specific clinical question: if the goal is to detect ischemia, anti-ischemic medications may need to be held; if the goal is to evaluate the effectiveness of medical therapy, medications should be continued.
| Drug Category | Examples | Interaction & Recommendation |
|---|---|---|
| Methylxanthines / Caffeine | Coffee, tea, chocolate, theophylline, aminophylline | Block adenosine receptors, invalidating vasodilator stress. Withhold for 24 hours before adenosine/dipyridamole stress. |
| Beta-blockers | Metoprolol, atenolol, bisoprolol, propranolol | May blunt heart rate response during exercise stress, reducing test sensitivity. Consider withholding 24–48 hours if detecting ischemia is the goal. |
| Calcium channel blockers | Diltiazem, verapamil, amlodipine, nifedipine | May reduce myocardial ischemia and mask perfusion defects. Consider withholding 24–48 hours depending on clinical indication. |
| Nitrates | Isosorbide mononitrate, nitroglycerin | May improve perfusion and mask ischemia. Withhold long-acting nitrates for 12–24 hours if ischemia detection is the goal. |
| Dipyridamole (oral) | Persantin | Potentiates effects of IV dipyridamole or adenosine stress. Withhold for 24 hours before pharmacological stress. |
| P-glycoprotein inhibitors | Cyclosporine, verapamil, ketoconazole | Tc-99m sestamibi is a P-glycoprotein substrate. Inhibitors may increase myocardial uptake; this is generally not clinically significant for standard imaging. |
It is worth noting that Tc-99m sestamibi is a known substrate of P-glycoprotein (P-gp), a membrane efflux transporter expressed in many tissues including the heart. P-gp actively pumps the tracer out of cells, and the rate of this efflux contributes to the washout kinetics observed on delayed imaging. Medications that inhibit P-gp (such as cyclosporine, verapamil, and certain azole antifungals) may theoretically increase intracellular retention of Tc-99m sestamibi. While this interaction has been extensively studied in the context of tumor imaging (where P-gp expression is associated with multidrug resistance), it is generally not clinically significant for routine myocardial perfusion imaging.
Certain breast cancer chemotherapy regimens that induce P-gp expression in tumor cells may affect the sensitivity of Tc-99m sestamibi breast imaging, as increased P-gp activity leads to rapid tracer efflux from resistant tumor cells. This property has, in fact, been investigated as a potential method for predicting multidrug resistance and chemotherapy response in breast cancer patients.
The most important practical interaction to be aware of is between caffeine and pharmacological vasodilator stress agents. Even small amounts of caffeine can completely block the vasodilatory effect of adenosine and dipyridamole, resulting in a false-negative study. Patients should be explicitly instructed to avoid all caffeine-containing products (coffee, tea, cola, energy drinks, chocolate, and certain medications) for at least 24 hours before the scheduled procedure.
What Is the Correct Dosage of Medimibi?
Unlike conventional medications where patients manage their own dosing, Medimibi is prepared and administered entirely by trained nuclear medicine professionals in licensed facilities. The “dose” in radiopharmaceutical terms refers to the administered activity of radioactivity, measured in megabecquerels (MBq) or millicuries (mCi), rather than a weight-based drug dose. The appropriate activity for each patient is determined by the nuclear medicine physician based on the clinical indication, the specific imaging protocol, the patient’s body weight, and the capabilities of the imaging equipment.
Adults – Myocardial Perfusion Imaging
| Protocol | First Injection | Second Injection | Timing |
|---|---|---|---|
| One-day rest–stress | 250–350 MBq (rest) | 750–1000 MBq (stress) | 3–4 hours apart |
| One-day stress–rest | 250–350 MBq (stress) | 750–1000 MBq (rest) | 3–4 hours apart |
| Two-day protocol | 600–900 MBq (Day 1) | 600–900 MBq (Day 2) | Separate days |
In the widely used one-day rest–stress protocol, a lower activity is administered first at rest, followed by a higher activity during stress several hours later. The higher stress activity is necessary to overcome the residual background from the first injection. The two-day protocol allows equal activities for both studies and may provide superior image quality, though it requires two separate visits. Modern stress-first protocols are increasingly favored when a normal stress study can obviate the need for the rest injection, reducing both radiation dose and examination time.
Adults – Parathyroid Scintigraphy
Parathyroid Imaging
A single intravenous injection of 600–900 MBq (16–24 mCi) of Tc-99m sestamibi is administered. Early images are acquired at approximately 15 minutes, and delayed images at 2–3 hours post-injection. SPECT/CT imaging may be performed for improved anatomical localization. Some centers use a dual-tracer subtraction technique combining Tc-99m sestamibi with iodine-123 or Tc-99m pertechnetate for thyroid imaging.
Adults – Breast Imaging
Breast Scintigraphy (Scintimammography)
A single intravenous injection of 740–1110 MBq (20–30 mCi) is typically administered into a vein on the contralateral arm to the breast with the suspected lesion. Imaging begins approximately 5–10 minutes after injection using a dedicated breast gamma camera or conventional gamma camera with the patient in the prone position.
Children and Adolescents
Pediatric dosing of Tc-99m sestamibi is calculated on a body weight basis according to the EANM Dosage Card or institutional protocols. The general principle is to use the minimum activity that will produce diagnostic-quality images. Typical cardiac imaging activities in children are approximately 5.6–7.4 MBq/kg (with defined minimum activities), adjusted based on age and body habitus. The decision to perform nuclear imaging in pediatric patients requires careful clinical justification and consideration of alternative non-ionizing modalities such as echocardiography or cardiac MRI.
Elderly Patients
No specific dose adjustment is required for elderly patients. Standard adult activities apply. However, the referring physician and nuclear medicine specialist should carefully consider the clinical indication, as elderly patients may have multiple comorbidities that affect the choice of stress protocol (for example, a preference for pharmacological stress over exercise in patients with limited mobility).
Radiopharmaceutical Preparation
The preparation of Tc-99m sestamibi from the Medimibi kit is performed by qualified radiopharmacy or nuclear medicine staff under aseptic conditions and in compliance with radiation safety regulations. The process involves adding a specified volume and activity of sodium pertechnetate Tc-99m injection to the Medimibi vial, followed by heating in a boiling water bath or dry heat block for approximately 10 minutes. After cooling and quality control testing (to verify radiochemical purity of ≥90%), the labeled product is ready for injection. The prepared radiopharmaceutical should be used within 6 hours of preparation.
Overdose
In the event of accidental administration of an excessive activity of Medimibi, the radiation dose to the patient should be estimated and appropriate follow-up measures implemented. Increasing fluid intake and encouraging frequent urination can help accelerate the elimination of the radiopharmaceutical from the body, thereby reducing the overall radiation dose. There is no specific antidote. The nuclear medicine physician will document the incident and monitor the patient as clinically indicated.
What Are the Side Effects of Medimibi?
Tc-99m sestamibi has an excellent safety profile established over more than three decades of clinical use in millions of patients worldwide. The administered mass of the sestamibi complex is in the microgram range – far below any pharmacologically active dose – meaning that true pharmacological side effects are extremely rare. Many of the adverse events reported during Medimibi procedures are attributable to the concomitant pharmacological stress agent (adenosine, dipyridamole, or regadenoson) or the exercise stress test itself rather than to Medimibi.
In clinical trials and post-marketing surveillance, the following side effects have been reported in association with Tc-99m sestamibi administration:
Common
May affect up to 1 in 10 people
- Metallic or bitter taste (dysgeusia) – transient, resolving within minutes
- Headache
Uncommon
May affect up to 1 in 100 people
- Nausea
- Flushing or warmth at injection site
- Dizziness
- Abdominal discomfort
- Fatigue
- Injection site pain or irritation
Rare
May affect up to 1 in 1,000 people
- Skin rash or pruritus (itching)
- Chest pain (usually related to stress test)
- Hypotension (low blood pressure)
- Fever
- Visual disturbances
Very Rare / Not Known
Reported in fewer than 1 in 10,000 people
- Anaphylactoid reactions (severe allergic reaction)
- Angioedema (swelling of face, lips, or throat)
- Urticaria (hives)
- Severe hypotension requiring medical intervention
The transient metallic taste is the most commonly reported side effect and is believed to result from the rapid transit of the radiotracer through the oral mucosa immediately after injection. It typically resolves spontaneously within 1–5 minutes and requires no treatment. Headache, when it occurs, is usually mild and self-limiting.
It is important to distinguish between adverse effects of Medimibi and those caused by the stress agent used during the procedure. Adenosine commonly causes transient chest tightness, flushing, dyspnea (shortness of breath), headache, and atrioventricular block – all of which resolve within 1–2 minutes of stopping the infusion due to its ultra-short half-life (less than 10 seconds). Dipyridamole may cause similar symptoms with longer duration (up to 15–20 minutes), which can be reversed with intravenous aminophylline. Regadenoson is a newer selective A2A adenosine receptor agonist with a more favorable side effect profile than non-selective agents. These stress-related effects are not caused by Medimibi itself.
Regarding long-term radiation effects, the stochastic risk of radiation-induced cancer from a single Medimibi study is estimated to be very small. Based on the effective dose of approximately 8–12 mSv from a standard one-day MPI protocol and applying conservative linear no-threshold (LNT) risk estimates, the lifetime attributable risk of fatal cancer is approximately 0.04–0.06% (or roughly 1 in 1,700 to 1 in 2,500). This risk must be weighed against the substantial diagnostic benefit of accurately identifying or excluding significant coronary artery disease, which carries a much higher mortality risk if left undiagnosed.
Although serious reactions are extremely rare, seek immediate medical attention if you experience difficulty breathing, swelling of the face or throat, severe rash, chest pain persisting more than 15 minutes after the stress test, or any symptom that causes concern. Nuclear medicine departments are equipped to manage adverse reactions, and medical staff are present throughout the procedure.
How Should Medimibi Be Stored?
Medimibi is a hospital-use pharmaceutical that is stored, prepared, and administered exclusively within nuclear medicine departments. Patients never take this product home and do not need to manage its storage. The following information is provided for completeness and for healthcare professionals involved in its handling.
- Unlabeled kit storage: Store the Medimibi kit at a temperature between 2 °C and 25 °C (36–77 °F). Protect from light. Do not freeze. The kit has a defined shelf life (typically 12–24 months from manufacture), and the expiration date is printed on the vial label and outer carton.
- After radiolabeling: Once the kit has been labeled with technetium-99m, the prepared Tc-99m sestamibi injection should be stored at room temperature (15–25 °C) and must be used within 6 hours of preparation. The vial should be stored with appropriate radiation shielding (lead or tungsten) and labeled with the activity, time of preparation, and expiration time.
- Radiation shielding: The labeled product emits gamma radiation and must be stored in appropriate shielded containers (lead vial shields, lead-lined safes, or designated hot labs) to minimize radiation exposure to personnel and the environment.
- Quality control: Before administration, the radiochemical purity of the prepared product must be verified (typically ≥90% by thin-layer chromatography). Products that fail quality control must not be administered and should be disposed of as radioactive waste.
- Disposal: Unused product, expired product, and all contaminated materials must be disposed of in accordance with national and institutional regulations for radioactive waste. Given the short half-life of Tc-99m (6.02 hours), most waste can be stored for decay (typically 10 half-lives, approximately 60 hours) before disposal as conventional pharmaceutical waste, subject to institutional protocols.
Transport of the unlabeled Medimibi kit does not require special radioactive material packaging. However, transport of the labeled (radioactive) product must comply with International Atomic Energy Agency (IAEA) regulations for the transport of radioactive materials and applicable national regulations.
What Does Medimibi Contain?
Medimibi is supplied as a multi-dose kit for the preparation of technetium Tc-99m sestamibi injection. Each kit contains lyophilized (freeze-dried) powder in a sealed glass vial under nitrogen atmosphere. The vial contents require the addition of sodium pertechnetate Tc-99m injection and subsequent heating to produce the final radiopharmaceutical product.
Composition
| Ingredient | Role | Amount per Vial |
|---|---|---|
| Tetrakis(2-methoxy-2-methylpropyl isocyanide) copper(I) tetrafluoroborate | Active substance (sestamibi ligand precursor) | 1.0 mg |
| Stannous chloride dihydrate (SnCl₂·2H₂O) | Reducing agent (reduces pertechnetate for labeling) | 0.075 mg (min) |
| L-Cysteine hydrochloride monohydrate | Antioxidant / stabilizer | 1.0 mg |
| Sodium citrate dihydrate | Buffer / complexing agent | 2.6 mg |
| Mannitol | Bulking agent / lyoprotectant | 20 mg |
| Nitrogen (headspace) | Inert atmosphere (prevents oxidation) | N/A |
After Radiolabeling
When sodium pertechnetate Tc-99m is added to the Medimibi kit and heated, the following reaction occurs: the stannous chloride reduces the pertechnetate ion (TcO₄¹) from the +7 oxidation state to a lower oxidation state, which then undergoes ligand exchange with the copper-sestamibi complex. The copper is displaced and replaced by technetium, forming the hexacoordinate lipophilic cation [Tc-99m(MIBI)₆]¹⁺ (technetium Tc-99m sestamibi). The resulting solution is a clear, colorless to pale yellow solution suitable for intravenous injection after passing quality control testing.
Pack Sizes and Appearance
Medimibi is supplied as a white to off-white lyophilized powder in glass vials sealed with rubber stoppers and aluminum crimp caps. Kits are typically available in packs of 5 or 10 vials, designed for multi-dose use in busy nuclear medicine departments. The unlabeled kit is a non-radioactive product. The radioactivity is provided separately by the technetium-99m generator system maintained within the nuclear medicine department.
Frequently Asked Questions About Medimibi
Medimibi (technetium Tc-99m sestamibi) is a radiopharmaceutical used primarily for three diagnostic imaging purposes: (1) myocardial perfusion imaging (MPI) to detect coronary artery disease and assess heart muscle viability, (2) parathyroid scintigraphy to locate overactive parathyroid glands in patients with hyperparathyroidism, and (3) breast imaging (scintimammography) as a supplementary tool when mammographic findings are inconclusive. It is one of the most widely used radiopharmaceuticals in nuclear medicine, with millions of studies performed annually worldwide.
The radiation dose from a Medimibi scan is relatively low and is considered safe when the procedure is clinically justified. A typical myocardial perfusion study delivers an effective dose of approximately 8–12 mSv, which is comparable to 3–5 years of natural background radiation exposure. The diagnostic benefit of accurately identifying or ruling out significant heart disease far outweighs this small radiation risk. Nuclear medicine physicians follow the ALARA principle (As Low As Reasonably Achievable) to minimize radiation exposure while maintaining diagnostic quality. After the procedure, the radioactivity decays naturally within hours (Tc-99m has a 6-hour half-life) and is eliminated from the body through normal excretion.
Preparation depends on the type of study being performed. For myocardial perfusion imaging: fast for 4–6 hours before the test, avoid all caffeine-containing products (coffee, tea, chocolate, energy drinks, certain medications) for 24 hours if pharmacological stress is planned, and consult your doctor about whether to temporarily withhold certain cardiac medications. Wear comfortable clothing and supportive shoes suitable for exercise if a treadmill stress test is planned. For parathyroid imaging, no special preparation is usually required. Your nuclear medicine department will provide specific instructions tailored to your scheduled procedure.
A complete myocardial perfusion study using a one-day protocol typically takes 3–4 hours in total, including the stress test, two injection periods, and two imaging sessions. Each imaging session lasts approximately 15–30 minutes. If a two-day protocol is used, the procedure is split across two separate visits, each lasting approximately 1.5–2 hours. For parathyroid scintigraphy, the procedure typically takes 3–4 hours total (early and delayed imaging sessions with waiting time in between). Plan to spend a half-day at the nuclear medicine department for most Medimibi procedures.
Yes, you can safely be around other people after a Medimibi injection. The amount of radioactivity administered is low, and the gamma radiation emitted is relatively weak. The radiation exposure to people around you is minimal and decreases rapidly as the Tc-99m decays (half-life of 6 hours). No special isolation precautions are needed. However, as a general precaution, it is advisable to avoid prolonged close contact with pregnant women and very young children for approximately 6–12 hours after the injection. Drink plenty of fluids and urinate frequently after the procedure to help eliminate the radioactivity from your body more quickly.
Yes, several alternatives exist for cardiac imaging depending on the clinical question. Other nuclear medicine tracers include thallium-201 chloride (an older myocardial perfusion agent) and technetium Tc-99m tetrofosmin (another Tc-99m-labeled myocardial perfusion agent with similar properties to sestamibi). Non-nuclear alternatives include stress echocardiography (using ultrasound to assess heart wall motion during stress), cardiac MRI with perfusion assessment, coronary CT angiography (which directly visualizes coronary artery anatomy), and PET myocardial perfusion imaging (using rubidium-82 or nitrogen-13 ammonia). Your cardiologist and nuclear medicine physician will recommend the most appropriate test based on your clinical situation, available expertise, and local resources.
References
- European Association of Nuclear Medicine (EANM). Procedural Guidelines for Myocardial Perfusion Scintigraphy with SPECT and SPECT/CT. Eur J Nucl Med Mol Imaging. 2023;50:2887–2936.
- American Society of Nuclear Cardiology (ASNC). ASNC Imaging Guidelines for SPECT Nuclear Cardiology Procedures: Stress, Protocols, and Tracers. J Nucl Cardiol. 2024;31:101873.
- Society of Nuclear Medicine and Molecular Imaging (SNMMI). Procedure Standard for Myocardial Perfusion Imaging. Version 4.0. 2023.
- Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m Hexakis 2-Methoxyisobutyl Isonitrile: Human Biodistribution, Dosimetry, Safety, and Preliminary Comparison to Thallium-201 for Myocardial Perfusion Imaging. J Nucl Med. 1989;30(3):301–311.
- Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM Appropriate Use Criteria for Cardiac Radionuclide Imaging. J Am Coll Cardiol. 2009;53(23):2201–2229.
- Cheung K, Wang TS, Farrell K, et al. American Thyroid Association Statement on Preoperative Imaging for Thyroid Cancer Surgery. Thyroid. 2023;33(1):7–28.
- European Medicines Agency (EMA). Medimibi – Summary of Product Characteristics. Last updated 2025.
- International Commission on Radiological Protection (ICRP). Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 128. Ann ICRP. 2015;44(2 Suppl).
- World Health Organization (WHO). Cardiovascular Diseases Fact Sheet. 2023. Available at: WHO Cardiovascular Diseases.
- British National Formulary (BNF). Technetium (99mTc) sestamibi. National Institute for Health and Care Excellence (NICE). 2025.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in nuclear medicine, cardiology, and clinical pharmacology with extensive experience in diagnostic imaging and radiopharmaceutical safety.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, EANM, ASNC).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.